Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1RA plus Banxia Xiexin Decoction for type 2 diabetes
ChiCTR2400086382Phase 4Not yet recruiting
- Sponsor
- Binzhou People's Hospital
- Start
- Jul 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of loxenatide and Banxia Xiexin Decoction in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Binzhou People's Hospital. Primary endpoint: gastrointestinal adverse reactions. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
loxenatideBanxia Xiexin Decoction
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400086382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086382.